Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Risk of cancer in patients with biopsy-proven giant cell arteritis|
|Citation:||Rheumatology, 2010; 49(4):756-759|
|Publisher:||Oxford Univ Press|
|Catherine L. Hill, Antonia Cole, Maureen Rischmueller, Thomas Dodd, Mark Coleman, Graeme Tucker and Peter Roberts-Thomson|
|Abstract:||Objective. Results of previous studies investigating the association between GCA and malignancy are conflicting. We performed a study of the risk of cancer in patients with biopsy-proven GCA. Methods. Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies from the major pathology laboratories in South Australia (SA). All subjects with biopsy-proven GCA were linked to the SA Cancer Registry to identify cases of cancer until 31 December 2006. Standardized incidence ratios (SIRs) for cancer were determined using the age- and gender-specific rates for SA. Results. There were 226 cases of biopsy-proven GCA (163 females and 63 males). Thirty-one cases were diagnosed with cancer, following the diagnosis of biopsy-proven GCA. There was no increased risk of cancer among those with biopsy-proven GCA, following the diagnosis of GCA compared with the general population (SIR 1.2; 95% CI 0.8, 1.6). Conclusion. This cohort study did not demonstrate any increased risk for malignancy in subjects with biopsy-proven GCA.|
|Keywords:||Giant cell arteritis; Malignancy; Epidemiology; Population.|
|Rights:||© The Author 2010. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.